期刊
VACCINE
卷 28, 期 3, 页码 730-736出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.10.074
关键词
Hepatitis B; Vaccine; Booster
资金
- GIaxoSmithKlme Biologicals
- GSK Biologicals
Booster vaccination against hepatitis B (HBV) is not currently recommended, although debate continues on the duration of protection after priming We assessed antibody persistence and immune memory to hepatitis B 20 years after priming with a recombinant HBV-vaccine during infancy. Infants were vaccinated at birth, 1, 2 and 12 months of age. A subset received a booster dose at Year 5. Antibody persistence was measured approximately yearly until Year 20 Immune memory was assessed by ad ministration of HBV booster dose At Year 20. anti-HBs seroprotection rates and GMCs tended to be higher in Year 5 boosted than unboosted recipients (83.9% versus 60.5%). After the Year 20 booster dose, anti-HBs anamnestic responses were within the same range 95.8% of subjects in both groups. Primary and booster vaccination with HBV-vaccine in infants induces sustained seroprotection and immune memory against hepatitis B for up to 20 years Higher persisting seroprotection rates in subjects boosted at Year 5 did not translate into apparent differences in immune memory in a high endemic country (C) 2009 Elsevier Ltd. All rights reserved
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据